An Open Letter to the Autism-Neurobiology, Molecular-Therapeutics, and Clinical-Intervention Communities: Translational Pathways in Autism Neuroscience — Human-BBB Delivery Evolution, Cross-Timescale Circadian–Hippocampal Coupling, Mature Cortical Assembloids, and Blinded Neurodiversity-Affirming Play Trials

Peter De Ceuster*

*Biomedical & Translational Neuroscience Working Note: AAV/CRISPRa Delivery, Assembloid Circadian Assays, and Blinded NDBI Trial Design,
(peterdeceuster5@gmail.com)

November 21, 2026

Abstract

This document is written as an open letter to investigators in autism spectrum disorder (ASD) neurobiology, molecular therapeutics, stem-cell assembloid modeling, circadian neuroscience, and pediatric clinical trial methodology. Across four exploratory preprints [1–4], we outlined a cross-disciplinary agenda linking directed protein evolution, cortical organoids, circadian–hippocampal timing, and play-based developmental interventions. Building constructively on those hypotheses, the present letter integrates those converging threads into a falsifiable translational pipeline grounded in current delivery limits, multi-timescale circuit physiology, and masked randomized trial methodology.

First, we direct protein and capsid evolution toward validated CNS bottlenecks: human transferrin-receptor blood–brain-barrier-crossing AAV capsids, compact CRISPR activation (dCas9-VP64/p300) for haploinsufficient risk genes (*SHANK3*, *CHD8*, *SYNGAP1*, *SCN2A*), and extracellular mRNA-display ligands. Second, we formalize circadian–hippocampal coupling as a cross-timescale modulatory model—where 24-hour molecular clocks gate sub-minute CA1/CA3 sequence plasticity—and upgrade organoid assays to long-term ($\geq$ 200–300 d) isogenic dorsal–ventral assembloids carrying site-specific `AAVS1` `PER2::luc` reporters. Third, we couple Naturalistic Developmental Behavioral Intervention (NDBI) play protocols with masked behavioral assessors, positive parasympathetic autonomic endpoints (HF-HRV/RMSSD), diurnal cortisol slopes, and autistic participatory co-design. Formal technical and bibliographic updates to the prior preprints [1–4] are documented separately in our companion *Announcement of Corrections* [5].

To move the cross-disciplinary hypotheses sketched in [1–4] toward experimentally testable clinical and preclinical benchmarks, we structure our updated translational program into six coordinated components.

(1) Directed evolution aimed at CNS delivery and haploinsufficiency rescue. To overcome primary translational bottlenecks in syndromic and monogenic ASD, directed-evolution pipelines should focus on three validated molecular interfaces:

- **Human blood–brain-barrier-crossing AAV capsids:** Because murine BBB-penetrant vectors such as `AAV-PHP.eB` rely on the mouse-specific GPI-anchored receptor `Ly6a`, capsid-library selection must target conserved human brain-endothelial receptors—exemplified by transferrin-receptor-binding capsids such as `BI-hTFR1` [6].
- **Compact CRISPRa epigenetic rescue bypassing packaging and HDR limits:** Restoring full-length coding sequences for large postsynaptic or chromatin-remodeling genes such as *SHANK3* ($\sim 5.2\,$kb cDNA) and *CHD8* ($\sim 7.7\,$kb cDNA) exceeds the $\sim 4.7\,$kb single-AAV packaging capacity, while post-mitotic neurons lack S/G2-phase homology-directed repair (HDR). Compact CRISPR activation (`dCas9-VP64/p300`) targeted to the endogenous promoter or enhancer of the intact wild-type allele [7]—complemented where appropriate by base or prime editing—circumvents both constraints (Eq. 1).
- **Extracellular synaptic ligands:** Rather than cell-impermeant intracellular peptides, mRNA-display macrocycles [8] and engineered nanobodies selected for CNS multiparameter optimization should target accessible extracellular ectodomains (e.g., GluN2B, mGluR5, and TrkB) to tune excitatory–inhibitory synaptic gain with tractable pharmacokinetics.

$$\text{cDNA}(\textit{SHANK3}) \approx 5.2\,\text{kb},\;\; \text{cDNA}(\textit{CHD8}) \approx 7.7\,\text{kb} > 4.7\,\text{kb}\;\; (\text{AAV limit}) \implies \text{dCas9-VP64/p300 CRISPRa} + \text{BI-hTFR1}, \tag{1}$$

(2) Cross-timescale coupling between 24-hour circadian clocks and hippocampal sequence coding. A central mechanistic question raised in [3] is how circadian disruption interacts with temporal cognition in ASD. Rather than treating 24-hour suprachiasmatic nucleus (SCN) transcriptional–translational feedback loops (`CLOCK/BMAL1/PER/CRY`) and 10^0–$10^1\,$s hippocampal CA1/CA3 "time cells" [9] (paced by theta oscillations across entorhinal–hippocampal circuits) as operating on the same timescale, their relationship should be tested as a *cross-timescale modulatory cascade* (Eq. 2). Specifically, circadian phase gates rhythmic hippocampal CREB, ERK, and mTOR signaling, modulating temporal sequence stability and memory consolidation across the day–night cycle in *Chd8* and *Shank3* genetic models [10, 11].

$$\tau_{\text{SCN}} \approx 24\,\text{h}\;(\text{CLOCK/BMAL1/PER/CRY}) \xrightarrow{\text{CREB/ERK/mTOR phase gating}} \tau_{\text{time-cell}} \approx 10^0\text{–}10^1\,\text{s}\;(\text{CA1/CA3}\;\theta\text{-sequences}), \tag{2}$$

Pharmacological probing of this axis should employ knockout-controlled small-molecule clock modulators such as the CRY stabilizer `KL001` and the CK1δ/ε inhibitor `PF-670462` [12] (avoiding compounds such as `SR9009` that display REV-ERB-independent off-target effects [13]), paired with dual MT1/MT2 melatonergic agonists (e.g., tasimelteon) and timed behavioral assays across light–dark phases.

(3) Long-term isogenic dorsal–ventral cortical assembloids and knock-in clock reporters. To capture excitatory–inhibitory microcircuit maturation alongside intrinsic cellular rhythmicity, early dorsal forebrain organoids should be upgraded to **CRISPR-isogenic dorsal–ventral cortical assembloids** [14, 15] carrying parallel *SHANK3*, *CHD8*, *SYNGAP1*, and *SCN2A* variants and matured beyond $\geq$ 200–300 days [16]. Incorporating medial ganglionic eminence (MGE) interneurons reduces hypoxia-associated subtype stress [15] and supports mature GABAergic inhibition. For circadian phenotyping, a `PER2::luc` reporter should be introduced by site-specific CRISPR HDR knock-in at the safe-harbor `AAVS1` locus in human iPSCs prior to differentiation, followed by dexamethasone synchronization and single-cell bioluminescence imaging.

(4) Blinded, neurodiversity-affirming NDBI play trials with autonomic endpoints. Translating the developmental play framework of [4] into rigorous pediatric evidence requires embedding child-led play sessions within established Naturalistic

Developmental Behavioral Intervention (NDBI) randomized controlled trial architectures—building on **JASPER** [17], **ESDM**, **PACT**, and **DIR/Floortime**, alongside the **Project AIM** meta-analytic benchmarks [18]. To guard against detection bias and align physiology with autonomic regulation (Eq. 3), trial protocols should pair *masked/blinded* behavioral coding (BOSCC, ESCS, DCMA) with validated vagal and neuroendocrine readouts—namely **increased** heart-rate variability (HF-HRV / RMSSD) reflecting parasympathetic engagement and steeper negative diurnal salivary cortisol slopes—alongside sensory-safety screening and autistic participatory co-design tracking well-being and camouflaging burden.

$$\Delta \mathrm{BOSCC}_{\mathrm{masked}} < 0, \qquad \Delta \mathrm{RMSSD/HF\text{-}HRV} > 0, \qquad \frac{d[\mathrm{Cortisol}]_{\mathrm{diurnal}}}{dt} < 0. \tag{3}$$

(5) Integrated translational matrix. Table 1 summarizes the four experimental and clinical pillars uniting [1–4] into testable preclinical and trial endpoints.

Table 1. Integrated translational pipeline, molecular modalities, and falsifiable endpoints across [1–4].

Translational Pillar	Target Mechanism & Modality	Falsifiable Preclinical / Clinical Endpoint
BBB & Epigenetic Rescue [1, 2]	`BI-hTFR1` human BBB AAV; compact `dCas9-VP64/p300` CRISPRa (Eq. 1); extracellular mRNA-display ligands	Brain-wide CNS transduction; $\geq 1.5\times$ WT mRNA/protein rescue in haploinsufficient neurons without AAV payload excess
Circadian–Hippocampal Coupling [3]	CREB/ERK/mTOR phase gating of CA1 sequences (Eq. 2); `KL001`, `PF-670462`, dual MT1/MT2 agonist	Time-of-day variance in CA1 replay/time-cell stability and temporal discrimination reversed by clock phase restoration
Cortical Assembloids [1, 3]	$\geq$ 200–300 d isogenic D–V assembloids (*SHANK3*, *CHD8*, *SYNGAP1*, *SCN2A*); iPSC `AAVS1` `PER2::luc`	Synchronized single-cell bioluminescence rhythms and normalized E/I burst dynamics across MGE-integrated networks
Blinded NDBI Play RCT [4]	JASPER/ESDM-aligned child-led play; autistic co-design and sensory-safety screening	Masked BOSCC/ESCS gains, ΔRMSSD/HF-HRV > 0, diurnal cortisol slope (Eq. 3), reduced masking distress

(6) Collaborative request to NIH/SFARI, organoid consortia, and autism clinical networks. We invite two coordinated evaluations: (i) preclinical testing of human-TfR1 AAV-mediated CRISPRa rescue in $\geq$ 200-day isogenic dorsal–ventral assembloids coupled with diurnal CA1 sequence recordings in vivo; and (ii) a pre-registered Phase II/III masked-assessor NDBI play RCT incorporating HF-HRV/RMSSD, diurnal cortisol, and co-designed quality-of-life endpoints. Together, Eqs. (1)–(3) and Table 1 establish an experimentally grounded roadmap advancing the exploratory cross-disciplinary synthesis of [1–4], while formal errata and verified citation updates for those preprints are archived in our companion *Announcement of Corrections* [5].

References

[1] P. De Ceuster, *Perspective: Molecular-Action Pathways for Autism Drug Discovery: Organoids, Circadian Dynamics, and Genetic Engineering*, Zenodo (2025), https://doi.org/10.5281/zenodo.16787215.

[2] P. De Ceuster, *Directed Evolution of the BpsA Carrier Protein Domain for Enhanced Activation by Non-Cognate 4'-Phosphopantetheinyl Transferases Implications for ASD Drug Discovery*, Zenodo (2025), https://doi.org/10.5281/zenodo.17074086.

[3] P. De Ceuster, *Integrating Circadian Rhythm and Neurobiology in Precision Medicine: A Novel Approach for Treating Severe Autism Through the Exploration of Time Cells and Genetic Mechanisms*, Zenodo (2025), https://doi.org/10.5281/zenodo.17074161.

[4] P. De Ceuster, *Play-Based Interventions for Promoting Positive Developmental Outcomes in Autism Spectrum Disorder: A Comprehensive Therapeutic Protocol Informed by Neuroscience, Developmental Psychology, and Positive Psychology.*, Zenodo (2025), https://doi.org/10.5281/zenodo.17074461.

[5] P. De Ceuster, *An Open Announcement of Corrections: Consolidated Technical, Methodological, and Bibliographic Updates Across Prior Interdisciplinary Preprints (2025–2026)*, Companion Corrigendum Working Paper (2026).

[6] Q. Huang *et al.*, *An AAV capsid reprogrammed to bind human transferrin receptor mediates brain-wide gene delivery*, Science 384, 1220–1227 (2024).

[7] N. Matharu *et al.*, *CRISPR-mediated activation of a promoter or enhancer rescues obesity caused by haploinsufficiency*, Science 363, eaau0629 (2019).

[8] T. Passioura and H. Suga, Chem. Commun. 53, 1931–1940 (2017).

[9] C. J. MacDonald, K. Q. Lepage, U. T. Eden, and H. Eichenbaum, Neuron 71, 737–749 (2011).

[10] R. J. Platt *et al.*, Cell Rep. 19, 335–350 (2017).

[11] A. M. Ingiosi *et al.*, eLife 8, e42819 (2019).

[12] Q.-J. Meng *et al.*, Proc. Natl. Acad. Sci. U.S.A. 107, 15240–15245 (2010).

[13] P. Dierickx *et al.*, Proc. Natl. Acad. Sci. U.S.A. 116, 12147–12152 (2019).

[14] F. Birey *et al.*, Nature 545, 54–59 (2017).

[15] A. Bhaduri *et al.*, Nature 578, 142–148 (2020).

[16] A. Gordon *et al.*, Nature Neurosci. 24, 331–342 (2021).

[17] C. Kasari *et al.*, J. Autism Dev. Disord. 40, 1045–1056 (2010); J. Child Psychol. Psychiatry 62 (2021).

[18] M. Sandbank *et al.*, Psychol. Bull. 146, 1–29 (2020); BMJ 383, e076733 (2023).